Haleon plc

HLN

NYSE · Specialty & Generic Drugs

$9.14

At close - Nov 6, 4:00 PM EST - USD

Market Cap$40.76B

P/E19.0x

52W High$11.28

Volume18.68M

VCP Research Verdict2026Q2

Margin Expansion Masks Revenue Stagnation and Overhang

Haleon's investment thesis centers on its ability to sustain margin expansion through cost discipline and pricing power, evidenced by gross margin improving to 66.0% in 2026Q2 from 61.4% in 2024Q4, and operating margin reaching 23.8%.

Explore valuation models

MARKET ACTION

HLN price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis

Fundamental Trajectory

Revenue stabilized around $5.5B per quarter with 3.0% growth in 2026Q2, while gross margin expanded to 66.0% and operating margin to 23.8%, driving net margin to 13.6%.

Analyst Consensus+11.6% target

Buy(4 analysts)

3 Buy1 Hold0 Sell

The Bull Case

Upside Catalysts

Strong revenue and EPS growth

Potential for revenue growth up to +5.0% and EPS growth of +8.0% if pricing power remains strong and cost cuts are realized ahead of schedule.

Analyst consensus and price target

Majority of analysts rate Haleon as Buy or Strong Buy, with a consensus 12-month price target of $10, implying +11.7% upside, and a bull case target of $20.

Portfolio of trusted brands

Haleon's strong portfolio includes well-known brands like Sensodyne, Advil, and Centrum, which are leaders in oral health, vitamins, and pain relief.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

HLN-6.62%

S&P 500 (^GSPC)+7.63%

1-Year Return

HLN-0.76%

S&P 500 (^GSPC)+9.69%

3-Year Return

HLN+19.26%

S&P 500 (^GSPC)+68.61%

5-Year Return

HLN+30.35%

S&P 500 (^GSPC)+56.65%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E5Y Low

19.0x

Forward P/E

21.9x

EV/EBITDA0th %ile

13.7x

FCF YieldCash Flow

6.5%

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

19.0x

33.3x

0th· Low

EV/EBITDA

13.7x

20.4x

0th· Low

Price/FCF

15.5x

21.6x

0th· Low

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

Bear$12.39+35.6%

Base (Fair)$22.77+149.1%

Bull$42.10+360.6%

$12.39 Bear$22.77 Base$42.10 Bull

Current Market Price: $9.14

Trades at a 59.9% discount to Base DCF ($22.77)

Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend

Revenue FY25

$11.03B-1.8% YoY

Net income FY25

$1.63B+13.1% YoY

Free cash flow FY25

$1.97B-3.9% YoY

Operating margin FY25

21.9%+2.2 pts YoY

ROIC (FY25)7.6%

Avg ROIC 5Y6%

ROE (FY25)10%

Piotroski Score8 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate7/12 (58%)

Revenue Beat Rate6/12 (50%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Jul 30, 2026	$0.28+3.6% vs $0.27	$7.5B+17.5% vs $6.4B
Q1 2026 Feb 25, 2026	$0.26+3.4% vs $0.25	$7.5B-0.8% vs $7.6B
Q4 2025 Oct 30, 2025	$0.14-42.8% vs $0.24	$7.5B+171.9% vs $2.8B
Q3 2025 Jul 31, 2025	$0.24-0.6% vs $0.24	$7.3B-3.0% vs $7.5B

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

4 Stories

Defense World·2d ago

BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head Contrast

BioHarvest Sciences (NASDAQ: BHST - Get Free Report) and Haleon (NYSE: HLN - Get Free Report) are both consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Profitability This table compares BioHarvest Sciences and Haleon's

Seeking Alpha·Oct 29, 2026

Haleon plc (HLN) Q3 2026 Sales/Trading Call Transcript

Zacks Investment Research·Oct 29, 2026

ASAIY or HLN: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Consumer Products - Discretionary sector might want to consider either Sendas Distribuidora S.A. Sponsored ADR (ASAIY) or Haleon PLC Sponsored ADR (HLN).

Proactive Investors·Oct 20, 2026

UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon

UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.

Filtered for Haleon plcMore Headlines

Compare before deciding

Benchmark HLN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Haleon plc (HLN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
HLNHaleon plcCurrent	$9.14	$40.76B	19.01	-1.81%	14.78%	9.98%	1.94%
KVUEKenvue Inc.	$19.31	$37.08B	22.01	-2.14%	10.88%	16.06%	4.26%
CHDChurch & Dwight Co., Inc.	$109.33	$25.91B	33.68	1.57%	12.41%	18.21%	1.08%
PGThe Procter & Gamble Company	$165.40	$385.15B	24.84	3.26%	18.23%	29.42%	2.55%
CLColgate-Palmolive Company	$96.56	$77.27B	37.58	1.4%	9.65%	399.22%	2.33%
PBHPrestige Consumer Healthcare Inc.	$42.98	$2.04B	13.19	-4.31%	13.29%	8.19%	—

Compare HLN vs Peers

Haleon plc (HLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs KVUE

Most directly comparable listed peer for HLN.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare HLN against a more recognizable public peer.

Peer Set

Compare Top 5

vs KVUE, CHD, PG, CL

Get notified when HLN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

HLN Frequently Asked Questions

Haleon plc (HLN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Haleon plc's revenue?

Haleon plc (HLN) reported $11.03B in revenue in fiscal year 2025. That is 30% more than the $8.48B of fiscal year 2019.

How fast is Haleon plc growing?

Haleon plc (HLN) revenue fell by 1.8% in fiscal year 2025, compared with the prior fiscal year.

Is HLN profitable?

Yes. Haleon plc (HLN) earned $1.63B in net income in fiscal year 2025 (a 14.8% net margin).

Dividend & Returns

Does HLN pay dividends?

Yes. Haleon plc (HLN) pays a dividend that yields 1.94% at the current price, a moderate yield.

What is HLN's return on equity?

Haleon plc (HLN) had a return on equity (ROE) of 10.0% in fiscal year 2025. That is below the market's typical 10-15%.

What is Haleon plc's free cash flow?

Haleon plc (HLN) generated $1.97B in free cash flow in fiscal year 2025.

What if you invested $1,000 in HLN back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Jul 30, 2026

$0.28+3.6%

vs $0.27

$7.5B+17.5%

vs $6.4B

Q1 2026

Feb 25, 2026

$0.26+3.4%

vs $0.25

$7.5B-0.8%

vs $7.6B

Q4 2025

Oct 30, 2025

$0.14-42.8%

vs $0.24

$7.5B+171.9%

vs $2.8B

Q3 2025

Jul 31, 2025

$0.24-0.6%

vs $0.24

$7.3B-3.0%

vs $7.5B

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

HLNHaleon plcCurrent

$9.14

$40.76B

19.01

-1.81%

14.78%

9.98%

1.94%

KVUEKenvue Inc.

$19.31

$37.08B

22.01

-2.14%

10.88%

16.06%

4.26%

CHDChurch & Dwight Co., Inc.

$109.33

$25.91B

33.68

1.57%

12.41%

18.21%

1.08%

PGThe Procter & Gamble Company

$165.40

$385.15B

24.84

3.26%

18.23%

29.42%

2.55%

CLColgate-Palmolive Company

$96.56

$77.27B

37.58

1.4%

9.65%

399.22%

2.33%

PBHPrestige Consumer Healthcare Inc.

$42.98

$2.04B

13.19

-4.31%

13.29%

8.19%

—